Insider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells 2,958 Shares of Stock

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 2,958 shares of the stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $22,392.06. Following the completion of the sale, the senior vice president now directly owns 131,416 shares of the company’s stock, valued at approximately $994,819.12. The trade was a 2.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Anthony D’adamio also recently made the following trade(s):

• On Tuesday, February 18th, Anthony D’adamio sold 4,380 shares of Bioventus stock. The shares were sold at an average price of $10.19, for a total value of $44,632.20.

Bioventus Trading Up 0.5 %

Shares of BVS stock opened at $7.82 on Friday. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The stock has a 50 day simple moving average of $9.35 and a two-hundred day simple moving average of $10.63. The company has a market cap of $640.80 million, a P/E ratio of -12.82 and a beta of 0.92.

Institutional Trading of Bioventus

Several hedge funds have recently modified their holdings of BVS. Tower Research Capital LLC TRC boosted its stake in Bioventus by 106.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after acquiring an additional 1,786 shares in the last quarter. Plato Investment Management Ltd acquired a new position in shares of Bioventus during the fourth quarter valued at about $38,000. GAMMA Investing LLC boosted its position in shares of Bioventus by 3,228.7% during the 1st quarter. GAMMA Investing LLC now owns 5,792 shares of the company’s stock worth $53,000 after purchasing an additional 5,618 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Bioventus in the 4th quarter valued at about $75,000. Finally, Quantbot Technologies LP bought a new stake in Bioventus in the 4th quarter valued at about $103,000. Institutional investors own 62.94% of the company’s stock.

Analyst Ratings Changes

Separately, Canaccord Genuity Group restated a “buy” rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, March 17th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.